Introduction Autoimmune hemolytic anemia (AIHA) is classified according to the direct
antiglobulin test (DAT) and thermal characteristics of the autoantibody into warm and cold …

Simple Summary The availability of Bruton's tyrosine kinase (BTK) inhibitor ibrutinib has
undoubtedly reshaped the initial management of chronic lymphocytic leukemia (CLL) …

Cold antibody-mediated autoimmune hemolytic anemia (cAIHA) is a rare disease, usually
related to an underlying indolent clonal B-cell lymphoproliferative disorder. Jalink and …

Simple Summary In chronic lymphocytic leukemia (CLL), immune alterations—affecting both
the innate and adaptive immunity—are very common. As a clinical consequence, patients …

Simple Summary This review analyzes the occurrence, clinical characteristics, and
prognostic impact and treatment of autoimmune hemolytic anemia (AIHA) in chronic …

Introduction Immune checkpoint inhibitors (ICI) are increasingly being used to treat
numerous cancer types. Together with improved recognition of toxicities, this has led to more …

Chronic lymphocytic leukemia (CLL) predominantly affects older adults, characterized by a
relapsing and remitting pattern with sequential treatments available for many patients …

A panel of chronic lymphocytic leukemia (CLL) experts from Tuscany propose a real-life
diagnostic and therapeutic approach CLL that considers the role of genomic and somatic …

Chronic lymphocytic leukemia (CLL) incidence increases with age reaching 37.9/100,000 in
patients over 85 years. Although there is no standardized geriatric tool specifically validated …

Several novel treatments for chronic lymphocytic leukemia (CLL) have been recently
approved based on the results of randomized clinical trials. However, real-world evidence …